Advances in osteoclast biology resulting from the study of osteopetrotic mutations

Human Genetics

Volumn 124, Issue 6, 2009, Pages 561-577

  Segovia Silvestre, T ^a   Neutzsky Wulff, A V ^a   Sorensen, M G ^a   Christiansen, C ^b   Bollerslev, J ^c   Karsdal, M A ^a   Henriksen, K ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BETA3 INTEGRIN; BONE MORPHOGENETIC PROTEIN; CATHEPSIN K; CHLORIDE CHANNEL; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; GELATINASE B; I KAPPA B KINASE GAMMA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PLECKSTRIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SOMATOMEDIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ALBERS SCHOENBERG DISEASE; ARTICLE; BONE REMODELING; CELL DIFFERENTIATION; CELL FUNCTION; CYTOLOGY; DISEASE MODEL; GENE MUTATION; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BONE REMODELING; BONE RESORPTION; CARBONIC ANHYDRASE II; CATHEPSINS; CHLORIDE CHANNELS; DISEASE MODELS, ANIMAL; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MODELS, BIOLOGICAL; MUTATION; OSTEOBLASTS; OSTEOCLASTS; OSTEOPETROSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; UBIQUITIN-PROTEIN LIGASES; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 58049100952     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00439-008-0583-8     Document Type: Article

References (191)

1. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, Halleen JM (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883-890
2. Albers-Schönberg HE (1904) Röntgenbilder einer seltenen Knockenerkrankung. Munch Med Wochenschr 5:365-368
3. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:1741-1754
4. Asotra S, Gupta AK, Sodek J, Aubin JE, Heersche JN (1994) Carbonic anhydrase II mRNA expression in individual osteoclasts under "resorbing" and "nonresorbing" conditions. J Bone Miner Res 9:1115-1122
5. Aubin JE (2001) Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2:81-94
6. Aubin, Lian JB, Stein GS (2006) Bone formation: Maturation and functional activities of osteoblast lineage cell., 6th edn, pp 20-29
7. Balemans W, Van Wesenbeeck L, Van Hul W (2005) A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int 77:263-274
8. Baron (2005) General principles of bone biology, 5th edn, pp 1-8
9. Baron R, Neff L, Louvard D, Courtoy PJ (1985) Cell-mediated extracellular acidification and bone resorption: Evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 101:2210-2222
10. Baylink DJ, Finkelman RD, Mohan S (1993) Growth factors to stimulate bone formation. J Bone Miner Res 8(Suppl 2):S565-S572
11. Benichou OD, Laredo JD, de Vernejoul MC (2000) Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): Clinical and radiological manifestations in 42 patients. Bone 26:87-93
12. Benichou O, Cleiren E, Gram J, Bollerslev J, de Vernejoul MC, Van Hul W (2001) Mapping of autosomal dominant osteopetrosis type II (Albers-Schonberg disease) to chromosome 16p13.3. Am J Hum Genet 69:647-654
13. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
14. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S (1989) Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855-857
15. Blair HC, Teitelbaum SL, Tan HL, Koziol CM, Schlesinger PH (1991) Passive chloride permeability charge coupled to H(+)-ATPase of avian osteoclast ruffled membrane. Am J Physiol 260:C1315-C1324
16. Blair HC, Borysenko CW, Villa A, Schlesinger PH, Kalla SE, Yaroslavskiy BB, Garcia-Palacios V, Oakley JI, Orchard PJ (2004) In vitro differentiation of CD14 cells from osteopetrotic subjects: Contrasting phenotypes with TCIRG1, CLCN7, and attachment defects. J Bone Miner Res 19:1329-1338
17. Blin-Wakkach C, Wakkach A, Sexton PM, Rochet N, Carle GF (2004) Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis. Leukemia 18:1505-1511
18. Bollerslev J (1989) Autosomal dominant osteopetrosis: Bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr Rev 10:45-67
19. Bollerslev J, Grontved A, Andersen PE Jr (1988) Autosomal dominant osteopetrosis: An otoneurological investigation of the two radiological types. Laryngoscope 98:411-413
20. Bollerslev J, Steiniche T, Melsen F, Mosekilde L (1989) Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: A study of two radiological types. Bone 10:19-24
21. Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T, Mosekilde L (1993) Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14:865-869
22. Bollerslev J, Ueland T, Landaas S, Marks SC Jr. (2000) Serum creatine kinase isoenzyme BB in mammalian osteopetrosis. Clin Orthop Relat Res 241-247
23. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA (1996) Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 271:12517-12524
24. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521
25. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342
26. Brandt S, Jentsch TJ (1995) ClC-6 and ClC-7 are two novel broadly expressed members of the CLC chloride channel family. FEBS Lett 377:15-20
27. Burr DB (2002) Targeted and nontargeted remodeling. Bone 30:2-4
28. Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V (2003) Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive osteopetrosis. Hum Genet 112:186-189
29. Campos-Xavier AB, Casanova JL, Doumaz Y, Feingold J, Munnich A, Cormier-Daire V (2005) Intrafamilial phenotypic variability of osteopetrosis due to chloride channel 7 (CLCN7) mutations. Am J Med Genet A 133:216-218
30. Chalhoub N, Benachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, Villa A, Vacher J (2003) Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 9:399-406
31. Chavassieux P, Asser KM, Segovia-Silvestre T, Neutzsky-Wulff AV, Chapurlat R, Boivin G, Delmas PD (2008) Mechanisms of the anabolic effects of teriparatide on bone: Insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 23:1076-1083
32. Chen W, Yang S, Abe Y, Li M, Wang Y, Shao J, Li E, Li YP (2007) Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet 16:410-423
33. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W (2001) Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10:2861-2867
34. Cohen MM Jr (2006) The new bone biology: Pathologic, molecular, and clinical correlates. Am J Med Genet A 140:2646-2706
35. Dai XM, Zong XH, Akhter MP, Stanley ER (2004) Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J Bone Miner Res 19:1441-1451
36. Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, Fortunati D, Ballanti P, Iacobini M, Luciani M, Devito R, Pinto R, Caniglia M, Lanino E, Messina C, Cesaro S, Letizia C, Bianchini G, Fryssira H, Grabowski P, Shaw N, Bishop N, Hughes D, Kapur RP, Datta HK, Taranta A, Fornari R, Migliaccio S, Teti A (2006) Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: Implications for diagnosis and treatment. J Med Genet 43:315-325
37. Del Fattore A, Cappariello A, Teti A (2008a) Genetics, pathogenesis and complications of osteopetrosis. Bone 42:19-29
38. Del Fattore A, Fornari R, Van Wesenbeeck L, de Freitas F, Timmermans JP, Peruzzi B, Cappariello A, Rucci N, Spera G, Helfrich MH, Van Hul W, Migliaccio S, Teti A (2008b) A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res 23:380-391
39. Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK (2002) Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 143:4038-4047
40. Dodds RA, Connor JR, James IE, Rykaczewski EL, Appelbaum E, Dul E, Gowen M (1995) Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling bone. J Bone Miner Res 10:1666-1680
41. Donnarumma M, Regis S, Tappino B, Rosano C, Assereto S, Corsolini F, Di Rocco M, Filocamo M (2007) Molecular analysis and characterization of nine novel CTSK mutations in twelve patients affected by pycnodysostosis. Mutation in brief #961. Online. Hum Mutat 28:524
42. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:12511-12516
43. Driessen GJ, Gerritsen EJ, Fischer A, Fasth A, Hop WC, Veys P, Porta F, Cant A, Steward CG, Vossen JM, Uckan D, Friedrich W (2003) Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: An EBMT report. Bone Marrow Transplant 32:657-663
44. Ducy P, Schinke T, Karsenty G (2000) The osteoblast: A sophisticated fibroblast under central surveillance. Science 289:1501-1504
45. Dupuis-Girod S, Corradini N, Hadj-Rabia S, Fournet JC, Faivre L, Le Deist F, Durand P, Doffinger R, Smahi A, Israel A, Courtois G, Brousse N, Blanche S, Munnich A, Fischer A, Casanova JL, Bodemer C (2002) Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother. Pediatrics 109:e97
46. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230
47. Everts V, Aronson DC, Beertsen W (1985) Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int 37:25-31
48. Everts V, Delaisse JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W (2002) The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17:77-90
49. Favus MJ, Bushinsky DA, Lemann J (2006) Regulation of calcium, magnesium, and phosphate metabolism. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn, Chap 13, pp 76-83
50. Feigin ME, Malbon CC (2008) OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling. Cell Signal 20:949-957
51. Findlay DM, Martin TJ (1997) Receptors of calciotropic hormones. Horm Metab Res 29:128-134
52. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
53. Fischer T, De Vries L, Meerloo T, Farquhar MG (2003) Promotion of G alpha i3 subunit down-regulation by GIPN, a putative E3 ubiquitin ligase that interacts with RGS-GAIP. Proc Natl Acad Sci USA 100:8270-8275
54. Flanagan AM, Sarma U, Steward CG, Vellodi A, Horton MA (2000) Study of the nonresorptive phenotype of osteoclast-like cells from patients with malignant osteopetrosis: A new approach to investigating pathogenesis. J Bone Miner Res 15:352-360
55. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A (2000) Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25:343-346
56. Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, Andolina M, Flanagan A, Horwitz EM, Mihci E, Notarangelo LD, Ramenghi U, Teti A, Van Hove J, Vujic D, Young T, Albertini A, Orchard PJ, Vezzoni P, Villa A (2003) Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res 18:1740-1747
57. Fratzl-Zelman N, Valenta A, Roschger P, Nader A, Gelb BD, Fratzl P, Klaushofer K (2004) Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 89:1538-1547
58. Fujita Y, Nakata K, Yasui N, Matsui Y, Kataoka E, Hiroshima K, Shiba RI, Ochi T (2000) Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization. J Clin Endocrinol Metab 85:425-431
59. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaisse JM (1998) The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273:32347-32352
60. Garnero P, Ferreras M, Karsdal MA, NicAmhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859-867
61. Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238
62. Gerritsen EJ, Vossen JM, Fasth A, Friedrich W, Morgan G, Padmos A, Vellodi A, Porras O, O'Meara A, Porta F (1994a) Bone marrow transplantation for autosomal recessive osteopetrosis. A report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. J Pediatr 125:896-902
63. Gerritsen EJ, Vossen JM, van Loo IH, Hermans J, Helfrich MH, Griscelli C, Fischer A (1994b) Autosomal recessive osteopetrosis: Variability of findings at diagnosis and during the natural course. Pediatrics 93:247-253
64. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654-1663
65. Gram J, Antonsen S, Horder M, Bollerslev J (1991) Elevated serum levels of creatine kinase BB in autosomal dominant osteopetrosis type II. Calcif Tissue Int 48:438-439
66. Graves AR, Curran PK, Smith CL, Mindell JA (2008) The Cl(-)/H(+) antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453:788-792
67. Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, Vezzoni P, Villa A, Frattini A (2008) Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 83:64-76
68. Haagerup A, Hertz JM, Christensen MF, Binderup H, Kruse TA (2000) Cathepsin K gene mutations and 1q21 haplotypes in at patients with pycnodysostosis in an outbred population. Eur J Hum Genet 8:431-436
69. Hannon RA, Clack G, Gallager N, Macpherson M, Marshall A, Eastell R (2005) The effect of AZ0530, a highly selective SRC inhibitor, on bone turnover in healthy males. Bone 36:SUppl 2 (Abstract nb OC042)
70. Hansdottir H, Franzson L, Prestwood K, Sigurdsson G (2004) The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 52:779-783
71. Hattner R, Epker BN, Frost HM (1965) Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206:489-490
72. Hayden JM, Mohan S, Baylink DJ (1995) The insulin-like growth factor system and the coupling of formation to resorption. Bone 17:93S-98S
73. Hayman AR, Jones SJ, Boyde A, Foster D, Colledge WH, Carlton MB, Evans MJ, Cox TM (1996) Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 122:3151-3162
74. Heaney C, Shalev H, Elbedour K, Carmi R, Staack JB, Sheffield VC, Beier DR (1998) Human autosomal recessive osteopetrosis maps to 11q13, a position predicted by comparative mapping of the murine osteosclerosis (oc) mutation. Hum Mol Genet 7:1407-1410
75. Helfrich MH (2003) Osteoclast diseases. Microsc Res Tech 61:514-532
76. Helfrich MH, Gerritsen EJ (2001) Formation of non-resorbing osteoclasts from peripheral blood mononuclear cells of patients with malignant juvenile osteopetrosis. Br J Haematol 112:64-68
77. Helfrich M, Crockett JC, Hocking LJ, Coxon FP (2007) The pathogenesis of osteoclast diseases: Some knowns, but still many unknowns. Bonekey Osteovision 4:61-77
78. Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537-1545
79. Henriksen Gram J, Hoegh-Andersen P, Jemtland R, Ueland T, Dziegiel MH, Schaller S, Bollerslev J, Karsdal MA (2005) Osteoclasts from patients with Autosomal Dominant Osteopetrosis type I (ADOI) caused by a T253I mutation in LRP5 are normal in vitro, but have decreased resorption capacity in vivo. Am J Pathol 167:1341-1348
80. Henriksen K, Sorensen MG, Nielsen Rh, Gram J, Schaller S, Dziegiel MH, Everts V, Bollerslev J, Karsdal MA (2006) Degradation of the organic phase of bone by osteoclasts: A secondary role for lysosomal acidification. J Bone Miner Res 21:58-66
81. Ho N, Punturieri A, Wilkin D, Szabo J, Johnson M, Whaley J, Davis J, Clark A, Weiss S, Francomano C (1999) Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein. J Bone Miner Res 14:1649-1653
82. Horton MA, Massey HM, Rosenberg N, Nicholls B, Seligsohn U, Flanagan AM (2003) Upregulation of osteoclast alpha2beta1 integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. Br J Haematol 122:950-957
83. Hou WS, Bromme D, Zhao Y, Mehler E, Dushey C, Weinstein H, Miranda CS, Fraga C, Greig F, Carey J, Rimoin DL, Desnick RJ, Gelb BD (1999) Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest 103:731-738
84. Howard GA, Bottemiller BL, Turner RT, Rader JI, Baylink DJ (1981) Parathyroid hormone stimulates bone formation and resorption in organ culture: Evidence for a coupling mechanism. Proc Natl Acad Sci USA 78:3204-3208
85. Huffer WE (1988) Morphology and biochemistry of bone remodeling: possible control by vitamin D, parathyroid hormone, and other substances. Lab Invest 59:418-442
86. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3:1285-1289
87. Jansen I, De Vries T, Ravesloot J, Everts V, Oude Elferink R (2006) Loss of anion exchanger 2 (Ae2) in mice results in osteopetrosis. J Bone Miner Res 21:SUppl 1 (Abstract 1256)
88. Janssens K, ten Dijke P, Janssens S, Van Hul W (2005) Transforming growth factor-beta1 to the bone. Endocr Rev 26:743-774
89. Johnson ML, Harnish K, Nusse R, Van HW (2004) LRP5 and Wnt signaling: A union made for bone. J Bone Miner Res 19:1749-1757
90. Karsdal Henriksen K (2007) Osteoclasts control osteoblast activity. BoneKey-Osteovision 4:19-24
91. Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467-476
92. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487-494
93. Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K (2008) Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 366:483-488
94. Kasper D, Planells-Cases R, Fuhrmann JC, Scheel O, Zeitz O, Ruether K, Schmitt A, Poet M, Steinfeld R, Schweizer M, Kornak U, Jentsch TJ (2005) Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 24:1079-1091
95. Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E (2005) Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36:159-172
96. Koay MA, Brown MA (2005) Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton. Trends Mol Med 11:129-137
97. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428:758-763
98. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK (2005) Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584-4596
99. Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, Hasan C, Bode U, Jentsch TJ, Kubisch C (2000) Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 9:2059-2063
100. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ (2001) Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205-215
101. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
102. Laitala T, Vaananen HK (1994) Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase. J Clin Invest 93:2311-2318
103. Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC (2006) ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 440:220-223
104. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y (2006) v-ATPase V(0) subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12:1403-1409
105. Li YP, Chen W, Liang Y, Li E, Stashenko P (1999) Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 23:447-451
106. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571
107. Li CY, Jepsen KJ, Majeska RJ, Zhang J, Ni R, Gelb BD, Schaffler MB (2006) Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 21:865-875
108. Manolagas SC (2000) Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137
109. Manolson MF, Yu H, Chen W, Yao Y, Li K, Lees RL, Heersche JN (2003) The a3 isoform of the 100-kDa V-ATPase subunit is highly but differentially expressed in large (≥10 nuclei) and small (≤nuclei) osteoclasts. J Biol Chem 278:49271-49278
110. Maranda B, Chabot G, Decarie JC, Pata M, Azeddine B, Moreau A, Vacher J (2008) Clinical and cellular manifestations of OSTM1-related infantile osteopetrosis. J Bone Miner Res 23:296-300
111. Margolis DS, Szivek JA, Lai LW, Lien YH (2008) Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice. Calcif Tissue Int 82:66-76
112. Marks SC Jr, Walker DG (1981) The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors. Am J Anat 161:1-10
113. Martin TJ (1993) Hormones in the coupling of bone resorption and formation. Osteoporos Int 3(Suppl 1):121-125
114. Martin TJ, Seeman E (2007) New mechanisms and targets in the treatment of bone fragility. Clin Sci (Lond) 112:77-91
115. Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81
116. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF, Baron R, Teti A (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311-320
117. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831
118. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL (2000) Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433-440
119. Meadows NA, Sharma SM, Faulkner GJ, Ostrowski MC, Hume DA, Cassady AI (2007) The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor. J Biol Chem 282:1891-1904
120. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, Majumdar S, Lanier LL, Lowell CA, Nakamura MC (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 101:6158-6163
121. Mulari MT, Qu Q, Harkonen PL, Vaananen HK (2004) Osteoblast-like cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro. Calcif Tissue Int 75:253-261
122. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949
123. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29
124. Nataf S, Anginot A, Vuaillat C, Malaval L, Fodil N, Chereul E, Langlois JB, Dumontel C, Cavillon G, Confavreux C, Mazzorana M, Vico L, Belin MF, Vivier E, Tomasello E, Jurdic P (2005) Brain and bone damage in KARAP/ DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol 166:275-286
125. Nesbitt SA, Horton MA (1997) Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276:266-269
126. Neutzsky-Wulff AV, Karsdal MA, Henriksen K (2008) Characterization of the bone phenotype in ClC-7-deficient mice. Calcif Tissue Int (online 29 Oct 2008)
127. Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, Desnick RJ, Gelb BD (1999) Determination of bone markers in pycnodysostosis: Effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14:1902-1908
128. Noble B (2003) Bone microdamage and cell apoptosis. Eur Cell Mater 6:46-55
129. Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, Reeve J, Skerry TM, Lanyon LE (2003) Mechanical loading: Biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol 284:C934-C943
130. Ogbureke KU, Zhao Q, Li YP (2005) Human osteopetroses and the osteoclast V-H+-ATPase enzyme system. Front Biosci 10:2940-2954
131. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ (1997) Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771
132. Pangrazio A, Poliani PL, Megarbane A, Lefranc G, Lanino E, Di Rocco M, Rucci F, Lucchini F, Ravanini M, Facchetti F, Abinun M, Vezzoni P, Villa A, Frattini A (2006) Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res 21:1098-1105
133. Parfitt AM (2002) Targeted and nontargeted bone remodeling: Relationship to basic multicellular unit origination and progression. Bone 30:5-7
134. Pata M, Heraud C, Vacher J (2008) OSTM1 bone defect reveals an intercellular hematopoietic crosstalk. J Biol Chem
135. Quarello P, Forni M, Barberis L, Defilippi C, Campagnoli MF, Silvestro L, Frattini A, Chalhoub N, Vacher J, Ramenghi U (2004) Severe malignant osteopetrosis caused by a GL gene mutation. J Bone Miner Res 19:1194-1199
136. Rajapurohitam V, Chalhoub N, Benachenhou N, Neff L, Baron R, Vacher J (2001) The mouse osteopetrotic grey-lethal mutation induces a defect in osteoclast maturation/function. Bone 28:513-523
137. Ramirez A, Faupel J, Goebel I, Stiller A, Beyer S, Stockle C, Hasan C, Bode U, Kornak U, Kubisch C (2004) Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis. Hum Mutat 23:471-476
138. Ravn P, Clemmesen B, Christiansen C (1999a) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237-244
139. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999b) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363-2368
140. Reinholt FP, Hultenby K, Heinegard D, Marks SC Jr, Norgard M, Anderson G (1999) Extensive clear zone and defective ruffled border formation in osteoclasts of osteopetrotic (ia/ia) rats: Implications for secretory function. Exp Cell Res 251:477-491
141. Robey PG, Boskey AL (2006) Extracellular matrix and biomineralization of bone. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn, Chap 3, pp 12-19
142. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508-1514
143. Roodman GD (1999) Cell biology of the osteoclast. Exp Hematol 27:1229-1241
144. Roodman GD (2006) Regulation of osteoclast differentiation. Ann N Y Acad Sci 1068:100-109
145. Rosen CJ (2003) The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr 13:25-38
146. Rzeszutek K, Sarraf F, Davies JE (2003) Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth. J Craniofac Surg 14:301-307
147. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453-13458
148. Sakagami N, Amizuka N, Li M, Takeuchi K, Hoshino M, Nakamura M, Nozawa-Inoue K, Udagawa N, Maeda T (2005) Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice. Micron 36:688-695
149. Salo J, Lehenkari P, Mulari M, Metsikko K, Vaananen HK (1997) Removal of osteoclast bone resorption products by transcytosis. Science 276:270-273
150. Sarnsethsiri P, Hitt OK, Eyring EJ, Frost HM (1971) Tetracycline-based study of bone dynamics in pycnodysostosis. Clin Orthop Relat Res 74:301-312
151. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J (2000) Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K. Bone 26:367-373
152. Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Helix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiodt CB, Sorensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaisse JM, Engsig MT, Karsdal MA (2004) The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144-1153
153. Schilling AF, Mulhausen C, Lehmann W, Santer R, Schinke T, Rueger JM, Amling M (2007) High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K. Osteoporos Int 18:659-669
154. Schinke T, Schilling AF, Baranowsky A, Huebner A, Schulz A, Zustin J,
155. Scimeca JC, Franchi A, Trojani C, Parrinello H, Grosgeorge J, Robert C, Jaillon O, Poirier C, Gaudray P, Carle GF (2000) The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 26:207-213
156. Seeman E, Delmas PD (2006) Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
157. Semba I, Ishigami T, Sugihara K, Kitano M (2000) Higher osteoclastic demineralization and highly mineralized cement lines with osteocalcin deposition in a mandibular cortical bone of autosomal dominant osteopetrosis type II: Ultrastructural and undecalcified histological investigations. Bone 27:389-395
158. Shah GN, Bonapace G, Hu PY, Strisciuglio P, Sly WS (2004) Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): Novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation. Hum Mutat 24:272
159. Silva IV, Cebotaru V, Wang H, Wang XT, Wang SS, Guo G, Devuyst O, Thakker RV, Guggino WB, Guggino SE (2003) The ClC-5 knockout mouse model of Dent's disease has renal hypercalciuria and increased bone turnover. J Bone Miner Res 18:615-623
160. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319
161. Sly WS, Hu PY (1995) Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 64:375-401
162. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE (1983) Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 80:2752-2756
163. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, Babul-Hirji R, Baric I, Canham N, Chitayat D, Dupuis-Girod S, Ellis I, Etzioni A, Fasth A, Fisher A, Gerritsen B, Gulino V, Horwitz E, Klamroth V, Lanino E, Mirolo M, Musio A, Matthijs G, Nonomaya S, Notarangelo LD, Ochs HD, Superti FA, Valiaho J, van Hove JL, Vihinen M, Vujic D, Vezzoni P, Villa A (2001) The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 10:1767-1773
164. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH (2007) Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39:960-962
165. Souraty N, Noun P, Djambas-Khayat C, Chouery E, Pangrazio A, Villa A, Lefranc G, Frattini A, Megarbane A (2007) Molecular study of six families originating from the Middle-East and presenting with autosomal recessive osteopetrosis. Eur J Med Genet 50:188-199
166. Takahashi H, Epker B, Frost HM (1964) Resorption precedes formative activity. Surg Forum 15:437-438
167. Taranta A, Migliaccio S, Recchia I, Caniglia M, Luciani M, De Rossi G, Dionisi-Vici C, Pinto RM, Francalanci P, Boldrini R, Lanino E, Dini G, Morreale G, Ralston SH, Villa A, Vezzoni P, Del Principe D, Cassiani F, Palumbo G, Teti A (2003) Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol 162:57-68
168. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464-475
169. Teti A, Blair HC, Teitelbaum SL, Kahn AJ, Koziol C, Konsek J, Zambonin-Zallone A, Schlesinger PH (1989) Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. J Clin Invest 83:227-233
170. Teti A, Migliaccio S, Taranta A, Bernardini S, De Rossi G, Luciani M, Iacobini M, De Felice L, Boldrini R, Bosman C, Corsi A, Bianco P (1999) Mechanisms of osteoclast dysfunction in human osteopetrosis: Abnormal osteoclastogenesis and lack of osteoclast-specific adhesion structures. J Bone Miner Res 14:2107-2117
171. Thompson ER, Baylink DJ, Wergedal JE (1975) Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in the rat. Endocrinology 97:283-289
172. Thompson DA, Kriss A, Taylor D, Russell-Eggitt I, Hodgkins P, Morgan G, Vellodi A, Gerritsen EJ (1998) Early VEP and ERG evidence of visual dysfunction in autosomal recessive osteopetrosis. Neuropediatrics 29:137-144
173. Tolar J, Teitelbaum SL, Orchard PJ (2004) Osteopetrosis. N Engl J Med 351:2839-2849
174. Tran VP, Vignery A, Baron R (1982) An electron-microscopic study of the bone-remodeling sequence in the rat. Cell Tissue Res 225:283-292
175. Vaananen HK, Horton M (1995) The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 108(Pt 8):2729-2732
176. Van Wesenbeeck L, Van Hul W (2005) Lessons from osteopetrotic mutations in animals: Impact on our current understanding of osteoclast biology. Crit Rev Eukaryot Gene Expr 15:133-162
177. Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, MacKay CA, Van Hul E, Timmermans JP, Vanhoenacker F, Jacobs R, Peruzzi B, Teti A, Helfrich MH, Rogers MJ, Villa A, Van Hul W (2007) Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest 117:919-930
178. Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M, Farina C (2000) A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 106:309-318
179. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411-422
180. Waguespack SG, Hui SL, White KE, Buckwalter KA, Econs MJ (2002) Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab 87:2212-2217
181. Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ (2003) Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18:1513-1518
182. Waguespack SG, Hui SL, Dimeglio LA, Econs MJ (2007) Autosomal dominant osteopetrosis: Clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J Clin Endocrinol Metab 92:771-778
183. Walker E, McGregor N, Poulton I, Pompolo S, Allan E, Quinn J, Gillespie M, Martin T, Sims NA (2008) Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res
184. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, Ahmed-Ansari A, Sell KW, Pollard JW, Stanley ER (1990) Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 87:4828-4832
185. Xiao ZS, Hjelmeland AB, Quarles LD (2004) Selective deficiency of the "bone-related" Runx2-II unexpectedly preserves osteoblast-mediated skeletogenesis. J Biol Chem 279:20307-20313
186. Xu J, Cheng T, Feng HT, Pavlos NJ, Zheng MH (2007) Structure and function of V-ATPases in osteoclasts: Potential therapeutic targets for the treatment of osteolysis. Histol Histopathol 22:443-454
187. Yarali N, Fisgin T, Duru F, Kara A (2003) Osteopetrosis and Glanzmann's thrombasthenia in a child. Ann Hematol 82:254-256
188. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337
189. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K (2006) Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111-121
190. Zheng MH, Fan Y, Wysocki S, Wood DJ, Papadimitriou JM (1993) Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization. J Bone Miner Res 8:113-118
191. Zou L, Zou X, Li H, Mygind T, Zeng Y, Lu N, Bunger C (2006) Molecular mechanism of osteochondroprogenitor fate determination during bone formation. Adv Exp Med Biol 585:431-441